BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 6,612,587 shares, a growth of 39.6% from the January 15th total of 4,737,947 shares. Approximately 11.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,545,992 shares, the short-interest ratio is presently 2.6 days. Based on an average daily trading volume, of 2,545,992 shares, the short-interest ratio is presently 2.6 days. Approximately 11.8% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of research firms recently commented on BCAB. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. Rodman & Renshaw started coverage on shares of BioAtla in a research note on Tuesday, January 13th. They set a “buy” rating and a $4.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.00.

BioAtla Stock Performance

BioAtla stock opened at $0.15 on Tuesday. BioAtla has a 1 year low of $0.14 and a 1 year high of $1.43. The firm has a 50 day moving average price of $0.46 and a 200 day moving average price of $0.59. The company has a market cap of $9.52 million, a price-to-earnings ratio of -0.13 and a beta of 1.11.

Institutional Investors Weigh In On BioAtla

A number of institutional investors have recently added to or reduced their stakes in BCAB. Sheets Smith Investment Management purchased a new position in shares of BioAtla in the 3rd quarter worth about $46,000. Woodline Partners LP acquired a new position in BioAtla during the first quarter valued at approximately $26,000. Susquehanna International Group LLP grew its stake in BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after buying an additional 177,760 shares during the period. Millennium Management LLC acquired a new stake in shares of BioAtla in the third quarter worth $235,000. Finally, Jane Street Group LLC increased its position in shares of BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares in the last quarter. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.